Fosun Pharma: The application for registration of a single anti-drug supplement for the injection of pyrethroids by Hanyu Pharmaceuticals was accepted.

The new drug is a monoclonal antibody biosypolysed drug developed by Fosun Pharma and is mainly used for the treatment of HER2-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
In August 2020, Hanyu Pharmaceuticals received a Drug Registration Certificate from the State Drug Administration for the treatment of her2-positive metastatic breast cancer, HER2-positive early breast cancer, HER2-positive metastatic gastric adenocarcinoma, or adenocarcinoma at the junction of the gastroesophageal esophageal.
this time to the State Drug Administration to apply for additional, mainly for the new drug "60mg / bottle" specifications, in order to expand the choice of clinical use.
As of the date of this announcement (October 19), Quto Zhu single resistance listed in China (excluding Hong Kong, Macao and Taiwan, the same between companies between 20), is Hessetine of Shanghai Roche Pharmaceutical Co., Ltd., and Hanquyou of Hanyu Pharmaceuticals.
2019, QutoZhu's sales in China were approximately RMB4,577 million, according to IQVIA CHPA.
as of September 2020, the Group's cumulative research and development investment in the new drug at this stage is approximately RMB852.55 million (unaudited).
source: Fosun Pharmaceuticals Announcement.